Trifluridine, Tipiracil Hydrochloride

• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer. Pending
  2025-523984-39-00 Phase II 3 countries Gilead Sciences Inc.
• Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus … Recruiting
  2024-520356-24-00 Phase II 5 countries Delcath Systems Inc.
• Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed… Recruiting
  2024-512484-31-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy. (SOLSTICE… Recruiting
  2024-516180-85-00 Phase III 4 countries Institut De Recherches Internationales Servier IRIS
• ROMANCE Recruiting
  2025-521319-38-00 Phase II 1 country Gruppo Oncologico Dell'Italia Meridionale
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting
  2025-522395-92-00 Phase III 3 countries Fondation Franc.Cancerologie Digestive
• – IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici… Recruiting
  2024-519929-38-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• Efficacy and safety of trifluridin/tipiracil in combination with nanoliposomal irinotecan as a second line therapy in patients with cholangi… Recruiting
  2024-517330-18-00 Phase II 1 country Heinrich-Heine-Universitaet Duesseldorf
• Sequential immunochemotherapy treatment with Pembrolizumab plus Dendritic Cell (DC) Vaccine followed by Trifluridine/Tipiracil plus Bevacizu… Recruiting
  2024-514053-30-00 Phase II 1 country Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
• Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting
  2023-508724-35-00 Phase II 1 country Unicancer
• Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting
  2024-512999-35-00 Phase II 1 country Unicancer
• Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trif… Recruiting
  2024-513723-16-00 Phase II 1 country Charite Universitaetsmedizin Berlin KöR
• Investigate the efficacy and safety of a bio-marker driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RA… Recruiting
  2024-518534-81-00 Phase II 1 country Gruppo Oncologico Dell'Italia Meridionale
• A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended
  2023-508276-11-00 Phase III 5 countries AstraZeneca AB
• A PHASE 1/2 STUDY EXPLORING THE SAFETY AND ACTIVITY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH CAPECITABINE AND BEVACIZUMAB IN METASTATIC… Ended
  2024-513271-41-00 Phase II 1 country Fondazione GONO G.I.
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended
  2022-501234-37-00 Phase I (FiH) 4 countries Regeneron Pharmaceuticals Inc.
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect… Ended
  2023-503797-21-00 Phase III 10 countries Bristol Myers Squibb International Corporation
• ​​Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300)​ Ended
  2024-511187-81-00 Phase III 5 countries Amgen Inc.
• TAS102 in patients with ER-positive, HER2-negative advanced breast cancer (TIBET study) Ended
  2024-519204-27-00 Phase II 1 country BOOG Study Center B.V.
• A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONS… Ended
  2024-512804-20-00 Phase III 6 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–20 of 20 trials